KR960704534A - 치료학적 전달 조성물 및 그의 사용 방법(therapeutic delivery compositions and method of use thereof) - Google Patents

치료학적 전달 조성물 및 그의 사용 방법(therapeutic delivery compositions and method of use thereof)

Info

Publication number
KR960704534A
KR960704534A KR1019960701930A KR19960701930A KR960704534A KR 960704534 A KR960704534 A KR 960704534A KR 1019960701930 A KR1019960701930 A KR 1019960701930A KR 19960701930 A KR19960701930 A KR 19960701930A KR 960704534 A KR960704534 A KR 960704534A
Authority
KR
South Korea
Prior art keywords
copolymer
approximately
molecular weight
nucleic acid
acid sequence
Prior art date
Application number
KR1019960701930A
Other languages
English (en)
Other versions
KR100218140B1 (ko
Inventor
마틴 엠마누엘 알.
에스. 알라우딘 하미드술탄
지. 코우소울라스 콘스탄틴
Original Assignee
잭 제이 루치이스
싸이트릭스 코오포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 잭 제이 루치이스, 싸이트릭스 코오포레이션 filed Critical 잭 제이 루치이스
Publication of KR960704534A publication Critical patent/KR960704534A/ko
Application granted granted Critical
Publication of KR100218140B1 publication Critical patent/KR100218140B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

본 발명은 유전자 치료법 및 안티센스 올리고뉴클레오티드 또는 다른 핵산 서열의 세포내 전달을 통해 감염성 질병 및 유전 장해를 치료하기 위한 조성물 및 방법에 관한 것이다. 본 발명은 핵산 서열 기능을 변경시킬 수 있는 효과량의 치료학적 화합물 및 하기 일반식을 갖는 효과량의 계면활성 비이온성 블록 공중합체의 투여 가능한 혼합물로 구성되는 질별 상태를 치료하기 위해 효과적인 치료학적 전달 조성물로 구성된다 : HO(C2H4O)b(C3H6O)a(C2H4O)bH. 상기식에서, a는 (C3H6O)에 0에 의해 표현된 소수성 부분이 약 750과 약 15,000 사이, 바람직하게 약 2250과 약 15,000 사이, 보다 바람직하게 약 3250과 약 15,000 사이의 분자량을 갖도록 하는 정수이고, b는 (C2H4O)의 의해 표현된 친수성 부분이 화합물의 중량으로 약 1% 내지 약 50%, 바람직하게 약 5% 내지 약 20%로 구성되도록 하는 정수이다.

Description

치료학적 전달 조성물 및 그의 사용 방법(THERAPEUTIC DELIVERY COMPOSITIONS AND METHOD OF USE THEREOF)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (16)

  1. 하기식의 비이온성 블록 공중합체와 혼합된, 핵산 서열 기능을 변화시킬 수 있는 화합물을 포함함을 특징으로 하는, 사람 또는 동물 치료용 치료 조성물.
    HO(C2H4O)b(C3H6O)a(C2H4O)bH
    상기 식에서, 공중합체의 폴리옥시프로필렌 부로 나타낸 분자량은 대략 750 내지 15,000이고, 공중합체의 폴리옥시에틸렌 부로 나타낸 분자량은 공중합체의 대략 1 내지 50%를 구성한다.
  2. 제1항에 있어서, 공중합체의 폴리옥시프로필렌 부로 나타낸 분자량이 대략 2250 내지 15,000이고, 공중합체의 폴리옥시에틸렌 부로 나타낸 분자량이 공중합체의 대략 5 내지 50%를 구성하는 조성물.
  3. 제1항에 있어서, 공중합체의 폴리옥시프로필렌 부로 나타낸 분자량이 대략 3250 내지 15,000이고, 공중합체의 폴리옥시에틸렌 부로 나타낸 분자량이 공중합체의 대략 5 내지 20%를 구성하는 조성물.
  4. 제1항에 있어서, 공중합체가 CRL-8131 또는 CRL-8142인 조성물.
  5. 제1항에 있어서, 핵산 서열 기능을 변화시킬 수 있는 화합물이 유전자, 올리고뉴클레오티드, 안티센스 올리고뉴클레오티드, 트리플렉스 DNA 화합물 및 리보자임으로 이루어진 그룹중에서 선택되는 조성물.
  6. 제7항에 있어서, 대략 0.1 내지 대략 5중량%의 계면활성제 및 대략 0.5 내지 대략 5용량%의 저분자량알콜을 추가로 포함하는 조성물.
  7. 제6항에 있어서, 계면활성제가 Tween 80이고, 알콜이 에탄올인 조성물.
  8. 제7항에 있어서, 핵산서열 기능을 변화시킬 수 있는 화합물이 발현 벡터에 함유된 핵산서열이고, 발현벡터가 헥산서열을 발현할 수 있는, 발현벡터를 추가로 포함하는 조성물.
  9. 하기식의 비이온성 블록 공중합체와 혼합된, 헥산서열 기능을 변화시킬 수 있는 화합물을 포함하는 조성물을 사람 또는 동물에 투여하는 단계를 포함하는, 핵산서열기능을 변화시킬 수 있는 화합물을 사람 또는 동물로 전달하는 방법.
    HO(C2H4O)b(C3H6O)a(C2H4O)bH
    상기 식에서, 공중합체의 폴리옥시프로필렌 부로 나타낸 분자량은 대략 750 내지 15,000이고, 공중합체의 폴리옥시에틸렌 부로 나타낸 분자량은 공중합체의 대략 1 내지 50%를 구성한다.
  10. 제9항에 있어서, 공중합체의 폴리옥시프로필렌 부로 나타낸 분자량이 대략 2250 내지 15,000이고, 공중합체의 폴리옥시에틸렌 부로 나타낸 분자량이 공중합체의 대략 5 내지 50%를 구성하는 방법.
  11. 제9항에 있어서, 공중합체의 폴리옥시프로필렌 부로 나타낸 분자량이 대략 3250 내지 15,000이고, 공중합체의 폴리옥시에틸렌 부로 나타낸 분자량이 공중합체의 대략 5 내지 20%를 구성하는 방법.
  12. 제9항에 있어서, 공중합체가 CRL-8131 또는 CRL-8142인 방법.
  13. 제9항에 있어서, 핵산 서열 기능을 변화시킬 수 있는 화합물이 유전자, 올리고뉴클레오티드, 안티센스 올리고뉴클레오티드, 트리플렉스 DNA 화합물 및 리보자임으로 이루어진 그룹중에서 선택되는 방법.
  14. 제9항에 있어서, 대략 0.1 내지 대략 5중량%의 계면활성제 및 대략 0.5 내지 약 5용량%의 저분자량알콜을 추가로 포함하는 방법.
  15. 제14항에 있어서, 계면활성제가 Tween 80이고, 알콜이 에탄올인 방법.
  16. 제9항에 있어서, 핵산서열 기능을 변화시킬 수 있는 화합물이 발현 벡터에 함유된 핵산서열이고, 발현벡터가 핵산서열을 발현할 수 있는, 발현벡터를 추가로 포함하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960701930A 1993-10-15 1994-10-12 치료학적 전달 조성물 및 그의 사용 방법 KR100218140B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13827193A 1993-10-15 1993-10-15
US138,271 1993-10-15
PCT/US1994/011594 WO1995010265A1 (en) 1993-10-15 1994-10-12 Therapeutic delivery compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
KR960704534A true KR960704534A (ko) 1996-10-09
KR100218140B1 KR100218140B1 (ko) 1999-09-01

Family

ID=22481270

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960701930A KR100218140B1 (ko) 1993-10-15 1994-10-12 치료학적 전달 조성물 및 그의 사용 방법

Country Status (9)

Country Link
EP (1) EP0723440B1 (ko)
JP (1) JP3819422B2 (ko)
KR (1) KR100218140B1 (ko)
AT (1) ATE230260T1 (ko)
AU (1) AU8076494A (ko)
DE (1) DE69431959T2 (ko)
DK (1) DK0723440T3 (ko)
ES (1) ES2189808T3 (ko)
WO (1) WO1995010265A1 (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1181937A3 (en) 1994-08-09 2004-02-04 Cytrx Corporation Novel vaccine adjuvant and vaccine
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US6673914B1 (en) 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
KR100360827B1 (ko) * 1999-08-14 2002-11-18 주식회사 삼양사 난용성 약물을 가용화하기 위한 고분자 조성물 및 그의 제조방법
US6875748B2 (en) 2000-04-21 2005-04-05 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
EP1232758A1 (fr) * 2001-02-19 2002-08-21 Aventis Pasteur Polynucléotide formulé en vue d'un transfert intracellulaire amélioré
AU2002366809A1 (en) 2001-12-20 2003-07-09 Schering-Plough Corporation Syn3 compositions and methods
CN100429220C (zh) 2003-06-04 2008-10-29 坎基股份有限公司 用于干扰素治疗的方法和组合物
SI3721888T1 (sl) 2013-02-05 2023-04-28 The Board Of Trustees Of The Leland Stanford Junior University Tarčne terapije proti CD47 za zdravljenje infekcijske bolezni

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3308458A1 (de) * 1983-03-10 1984-09-13 Behringwerke Ag, 3550 Marburg Verfahren zur adjuvierung von vaccinen
IT1191608B (it) * 1985-02-01 1988-03-23 Zambon Spa Composizione farmaceutica e forme farmaceutiche che la contengono
AU6334586A (en) * 1986-05-15 1987-12-01 Emory University Composition and method for treating a thrombus and embolus
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US5221495A (en) * 1990-04-13 1993-06-22 Colgate-Palmolive Company Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions
HUT67762A (en) * 1991-03-19 1995-04-28 Cytrx Corp Polyoxypropylene/polyoxiethylene copolymers with improved biological activity and process for producing thereof
WO1993008845A1 (en) * 1991-11-08 1993-05-13 Massachusetts Institute Of Technology Localized oligonucleotide therapy

Also Published As

Publication number Publication date
EP0723440A4 (en) 1997-06-11
ES2189808T3 (es) 2003-07-16
DK0723440T3 (da) 2003-02-24
JPH09503788A (ja) 1997-04-15
DE69431959D1 (de) 2003-02-06
JP3819422B2 (ja) 2006-09-06
KR100218140B1 (ko) 1999-09-01
AU8076494A (en) 1995-05-04
EP0723440A1 (en) 1996-07-31
EP0723440B1 (en) 2003-01-02
WO1995010265A1 (en) 1995-04-20
ATE230260T1 (de) 2003-01-15
DE69431959T2 (de) 2003-11-06

Similar Documents

Publication Publication Date Title
KR960704534A (ko) 치료학적 전달 조성물 및 그의 사용 방법(therapeutic delivery compositions and method of use thereof)
DE69028694T2 (de) Verfahren und zubereitungen zur krebsbehandlung mit oligonukleotiden
EP1432452B1 (de) Inhibition von stat-1
MX9406552A (es) Metodo, composiciones y dispositivos para la admi nistracion de polinucleotidos desnudos que codifi can peptidos biologicamente activos.
WO2003033700A1 (de) Verfahren zur hemmung der replikation von viren
US20130324586A1 (en) Inhibition of Hairless Protein mRNA
US20100015708A1 (en) Ribonucleic acids with non-standard bases and uses thereof
WO2006003481A3 (en) Oleaginous pharmaceutical and cosmetic foam
EP1182206A2 (de) Stabiliserte Oligonucleotide und deren Verwendung
ES2732351T3 (es) ARNip y su uso en métodos y composiciones para el tratamiento y/o la prevención de afecciones oculares
US20240167028A1 (en) Methods of treating osmidrosis
EP0772621A2 (en) Oligonucleotides with anti-mdr-1 gene activity
Henry et al. Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication
CA3141762A1 (en) Methods for the treatment of alpha-1 antitrypsin deficiency (aatd)
FR2790757B1 (fr) Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
KITAJIMA et al. Phosphorothioate oligodeoxynucleotides inhibit basic fibroblast growth factor-induced angiogenesis in vitro and in vivo
ES2176360T3 (es) Combinacion de vehiculos de administracion de genes.
DE10148828B4 (de) Modulation der Expression STAT-1-abhängiger Gene
DE69302369T2 (de) Erhöhung der katalytischen Aktivität von Ribozymen mit einem benachbartem Oligonukleotid als Heffer
JP2006505290A5 (ko)
US20170253879A1 (en) APTAMER-RNAi THERAPEUTIC COMPOSITIONS
CA2174122A1 (en) Therapeutic delivery compositions and methods of use thereof
WO1997004087A1 (de) Ribozyme zur selektiven hemmung der expression von genen von mhc-allelen und diese enthaltende arzneimittel
Tarnow When extra authors get in on the act
DE102018114467A1 (de) Erfindung betreffend Prophylaxe und Therapie gegen NPC-1-sensitive Viren

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20041202

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee